Rivotril Brand

$10 per pill

Commercial Name: Klonopin, Rivotril

Active Ingredient: Clonazepam

Production form: Pills

Utilization: Anti-Anxiety

Available Dosage: 2mg

Shopping Event

Hurry and get Discount on all Our product 10% OFF Use this code and Get Discount

YN31R6L448s

$80.00

Compare

Add to wishlist

Pick up from Steroid Gear Shop

To pick up today

Free

Courier delivery

Our courier will deliver to the specified address

2-3 Days

$35

DHL Courier delivery

DHL courier will deliver to the specified address

2-3 Days

$35

FedEx Courier delivery

FedEx courier will deliver to the specified address

2-3 Days

$35

Warranty 6 Month

Free 30-Day returns

More details

Payment Methods:

Description

Rivotril is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, Rivotril may be useful.

SIDE EFFECTS

The adverse experiences for Rivotril are provided separately for patients with seizure disorders and panic disorder.

Seizure Disorders

The most frequently occurring side effects of Rivotril are referable to CNS depression. Experience in treatment of seizures has shown that drowsiness has occurred in approximately 50% of patients and ataxia in approximately 30%. In some cases, these may diminish with time; behaviour problems have been noted in approximately 25% of patients. Others, listed by system, including those identified during postapproval use of Rivotril are:

Cardiovascular: Palpitations
Dermatologic: Hair loss, hirsutism, skin rash, ankle and facial oedema
Gastrointestinal: Anorexia, coated tongue, constipation, diarrhoea, dry mouth, encopresis, gastritis, increased appetite, nausea, sore gum
Genitourinary: Dysuria, enuresis, nocturia, urinary retention
Hematopoietic: Anemia, leukopenia, thrombocytopenia, eosinophilia
Hepatic: Hepatomegaly, transient elevations of serum transaminases and alkaline phosphatase
Musculoskeletal: Muscle weakness, pains
Miscellaneous: Dehydration, general deterioration, fever, lymphadenopathy, weight loss or gain
Neurologic: Abnormal eye movements, aphonia, choreiform movements, coma, diplopia dysarthria, dysdiadochokinesis, ‘‘glassy-eyed’’ appearance, headache, hemiparesis, hypotonia, nystagmus, respiratory depression, slurred speech, tremor, vertigo
Psychiatric: Confusion, depression, amnesia, hysteria, increased libido, insomnia, psychosis (the behavior effects are more likely to occur in patients with a history of psychiatric disturbances)
The following paradoxical reactions have been observed: irritability, aggression, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares, abnormal dreams, hallucinations.
Respiratory: Chest congestion, rhinorrhea, shortness of breath, hypersecretion in upper respiratory passages

Panic Disorder

Adverse events during exposure to Rivotril were obtained by spontaneous report and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, CIGY dictionary terminology has been used to classify reported adverse events, except in certain cases in which redundant terms were collapsed into more meaningful terms, as noted below.

The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.

Adverse Findings Observed In Short-Term, Placebo-Controlled Trials

Adverse Events Associated With Discontinuation Of Treatment

Overall, the incidence of discontinuation due to adverse events was 17% in Rivotril compared to 9% for placebo in the combined data of two 6- to 9-week trials.